The RELIANCE Trial provided the first demonstration of licensure-quality CAR-T manufacturing and clinical trial data generation in r/r patients originating in China. These results with relma-cel demonstrate similar preliminary response rates and PK profiles while providing the potential for an improved toxicity profile in heavily-pre-treated patients with r/r DLBCL having poor risk features relative to other CD19-specific CAR-Ts approved in the US and EU.

We have strategically built a comprehensive and differentiated product pipeline of cellular immunotherapy, covering a variety of next-generation approaches that improve the risk-to-benefit ratio of our products, including allogeneic approaches, combination strategies with small molecules and other CAR-T products with new gene modifications. We believe that our product candidates have the potential to be the ground-breaking therapies in their respective indications.